Destro 9x8 Page

While immunotherapy has revolutionized cancer treatment, many colorectal cancers (specifically MSS/pMMR) have historically responded poorly to single-agent immunotherapy.

CheckMate 9X8 is part of a broader field of study, alongside trials like AtezoTRIBE and MEDITREME, testing similar immunotherapeutic approaches. 4. Preliminary Findings & Objectives Destro 9x8

The study aims to enhance antitumor immune responses in treatment-naïve patients (those who have not previously received treatment) with mCRC. While immunotherapy has revolutionized cancer treatment

Combining chemotherapy with ICIs like nivolumab aims to convert "cold" tumors (non-responsive) into "hot" tumors (immune-active). alongside trials like AtezoTRIBE and MEDITREME